CXCL9 and non-small cell lung carcinoma: In contrast to our observations in patients with stage I NSCLC, we did not observe any association between the interferon-inducible chemokines (CXCL9/CXCL10/CXCL11) or IFN/ISG response activity and PFS (Figure S2).